更新于：2024-12-26
Rocbrutinib
洛布替尼
更新于：2024-12-26
概要
基本信息
原研机构 |
非在研机构- |
最高研发阶段临床2期 |
首次获批日期- |
最高研发阶段(中国)临床2期 |
特殊审评突破性疗法 (中国) |
登录后查看时间轴
结构
分子式C42H51N9O5 |
InChIKeyOYJVFTNYBWVQHA-SANMLTNESA-N |
CAS号2485861-07-0 |
关联
13
项与 洛布替尼 相关的临床试验A Phase Ib Study to Assess Safety and Preliminary Efficacy of Rocbrutinib in Combination With R-CHOP in Patients With Newly Diagnosed B-NHL
This is an open-label, multicentre Phase Ib study to evaluate the safety and preliminary efficacy of new generation Bruton Tyrosine Kinase inhibitor Rocbrutinib in combination to R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristin, Prednison) in adult patients with newly diagnosed, previously untreated B-cell Non-Hodgkin Lymphoma [Diffuse Large B-cell Lymphoma (DLBCL), Marginal Zone Lymphoma (MZL) or Mantle Cell Lymphoma (MCL)].
开始日期2024-04-10 |
申办/合作机构 |
一项评估LP-168联合R-CHOP方案治疗初治B细胞淋巴瘤有效性和安全性的Ib期研究
主要目的: 评估LP-168联合R-CHOP（利妥昔单抗、环磷酰胺、长春新碱、多柔比星、泼尼松）方案在B细胞淋巴瘤患者的安全性、耐受性、剂量限制性毒性（DLT）、药代动力学（PK）特征，确定联合方案的最大耐受剂量（MTD）和III期推荐剂量（RP3D）。次要目的: 评估LP-168联合R-CHOP方案治疗B细胞淋巴瘤患者的初步疗效，包括但不限于总体缓解率（ORR）、完全缓解率（CRR）、缓解持续时间（DOR）、PFS、无事件生存期（EFS）以及总生存期（OS）。探索性研究目的：探索与LP-168联合R-CHOP方案临床疗效相关的生物标志物；评估外周血微小残留病（MRD）与LP-168联合R-CHOP方案临床疗效及预后的关系。
开始日期2024-04-03 |
申办/合作机构 |
The Mass Balance Study of [14C]LP-168 in Chinese Healthy Subjects
This study is a single-center, open-label, single-dose clinical pharmacokinetic study. The purpose of this study is to investigate the absorption characteristics, as well as to evaluate the metabolism and elimination pathways after a single oral dose of 150mg, 100μCi [14C]LP-168 in healthy subjects.
开始日期2023-12-25 |
申办/合作机构 |
100 项与 洛布替尼 相关的临床结果
登录后查看更多信息
100 项与 洛布替尼 相关的转化医学
登录后查看更多信息
100 项与 洛布替尼 相关的专利（医药）
登录后查看更多信息
31
项与 洛布替尼 相关的新闻（医药）2024-12-19
·贝壳社
▲点击图片，了解详情
作者：嘤嘤嘤
12月16日，信达生物和礼来制药共同宣布，就礼来非共价（可逆）BTK抑制剂捷帕力®（匹妥布替尼100毫克和50毫克片剂）在中国大陆的权益达成以下合作协议：信达生物将负责捷帕力的进口、销售、推广和分销工作；礼来将负责捷帕力的研发和上市后医学事务相关工作。
套细胞淋巴瘤（MCL）是一种非霍奇金淋巴瘤（NHL）亚型，占所有NHL病例的约6%。MCL的命名来自其发病区域——套区，也就是淋巴结中的环形细胞，B细胞（一种淋巴细胞）产生于此并发挥特定的功能。从表现上来看，MCL可以是侵袭性的，也可以是快速增长的。虽然目前MCL没有治愈方法，但有一些治疗方案可能有助于控制MCL。然而，MCL的预后相对较差，有着巨大的临床未满足需求。
1
匹妥布替尼的优势
捷帕力®（匹妥布替尼片）是一种高选择性BTK抑制剂。由于其采用的是新型非共价结合机制，因此可以在既往接受过共价BTK抑制剂（已上市的包括伊布替尼、阿可替尼、泽布替尼、或奥布替尼）治疗的MCL患者中重新建立BTK抑制作用，并持续获益。大大满足了这部分患者的临床治疗需求。
匹妥布替尼于2023年1月获得美国FDA批准，成为全球首个且唯一获批的非共价（可逆）BTK抑制剂。于2024年10月获得我国国家药品监督管理局（NMPA）批准，单药适用于既往接受过至少两种系统性治疗（含BTK抑制剂）的复发或难治性MCL成人患者。
在中国2期临床试验JZNJ研究（开放标签、II期、单臂、多中心研究）中，研究者评估了匹妥布替尼单药治疗在中国B细胞恶性肿瘤患者中的疗效和安全性。该研究共纳入了87名中国B细胞恶性肿瘤患者，其中35名是曾接受过BTK抑制剂治疗的MCL患者。来自这35名患者的研究结果显示，经独立评审委员会评估确定的总体缓解率（ORR）为62.9%（95% CI：44.9-78.5）。
在中国人群中，匹妥布替尼的耐受性良好，未出现新的安全性信号，仅3%的患者因治疗相关不良反应而停药。中国研究结果与全球BRUIN研究结果一致，表明匹妥布替尼在中国人群中具有临床意义和持久的抗肿瘤活性。礼来之所以选择与信达生物合作，考虑的是充分利用信达生物在血液肿瘤领域丰富的商业化经验。
2
BTK抑制剂的成果
BTK是B细胞受体（BCR）信号通路中的重要组成部分，而BCR信号通路在B细胞的增殖、分化、发育和存活中起着关键作用。BTK的异常活化会导致BCR信号通路过度活跃，这与B细胞恶性肿瘤的发生、发展密切相关。因此，BTK成为B细胞肿瘤治疗的重要靶点。BTK抑制剂通过抑制BTK的自我磷酸化抑制其活性，从而阻断B细胞受体下游信号通路，诱导恶性B细胞凋亡。
最近十年来，BTK抑制剂一路高歌猛进，几乎称霸血液瘤领域，市场规模也已超百亿美元。越来越多的玩家参与进来，提供新的治疗选择，优化治疗策略。与此同时，市场竞争也变得越来越激烈。第一代不可逆抑制剂有伊布替尼，第二代不可逆抑制剂有泽布替尼、阿可替尼、奥布替尼、替拉鲁替尼，第三代可逆抑制剂匹妥布替尼。
由艾伯维与强生开发的首款BTK抑制剂伊布替尼2013年在美国获批上市，此后持续放量。其2021年全球销售额逼近百亿美元，之后有所下滑，2023年仍有超60亿美元（约合人民币436.76亿元）的销售收入。
二代BTK抑制剂也在近年来持续放量。2024年上半年，百济神州的泽布替尼销售额达到11.26亿美元，诺诚建华的奥布替尼2024年上半年销售额为4.2亿元，同比增长30%。根据弗若斯特沙利文数据，全球BTK抑制剂市场规模预计2025年达219亿美元，2030年达251亿美元。
此外，正在研究中的小野制药的Tirabrutinib是第二代高选择性共价BTK抑制剂，已在日本获批用于复发性和难治性原发性中枢神经系统淋巴瘤治疗，并正在中国等地进行更多适应症的研发。宜诺凯的奥布替尼于2021年6月被美国FDA指定为复发性和难治性MCL的突破性疗法，目前正在更多的适应症中进行研发。
Telios Pharma的TL-895（以前称为M7583）是另一款高效、高选择性的第二代BTK抑制剂，临床试验显示其在多种B细胞恶性肿瘤中疗效显著。浙江海正药业的DTRMWXHS-12则是另一款选择性共价BTK抑制剂，正在与mTOR抑制剂及免疫调节剂联用进行临床试验。
3
非共价BTK抑制剂的发展
从作用机制看，趋势是从不可逆共价升级到可逆非共价。不可逆抑制剂的治疗作用较强，可提高药物利用效率，但在高浓度下存在一定的脱靶毒性，如果患者产生BTK耐药突变，疗效将大打折扣。而可逆抑制剂则副作用较小，已经成为BTK抑制剂开发和应用领域的前沿。
除了联合疗法外，共价与非共价双重抑制剂正在开发中，取长补短，旨在最大限度地减少副作用并降低耐药性。LP-168就是这样一种双重抑制剂，能够根据突变是否存在进行共价和非共价结合。一项1期研究（NCT04993690）已经验证了LP-168的安全性和有效性。另一项1期研究（NCT04775745）发现，LP-168在患者中具有良好的耐受性，高达300mg的剂量都没有达到最大耐受剂量。
从clinicaltrials网站查询结果来看，目前开放中的BTK抑制剂临床试验有80多个，其中匹妥布替尼有17项。其他第三代BTK抑制剂包括默克的奈米他替尼、Aptose Biosciences的Luxeptinib以及和黄医药的HMPL-760等。奈米他替尼通过氢键可逆抑制野生型和C481S突变型BTK，但选择性较低。Luxeptinib是一种多激酶抑制剂，能非共价抑制多种激酶，包括野生型和突变型BTK、FLT3等。HMPL-760是一种高效、选择性、可逆BTK抑制剂，临床前模型显示其抑制活性高于匹妥布替尼片。
结语
相较于第一代BTK抑制剂，第二代BTK抑制剂在安全性上有显著提高，而非共价可逆BTK抑制剂的加入，为未来的临床治疗提供了更多的选择。BTK抑制剂单药或联合治疗模式在MCL治疗中逐渐成为趋势，并且有望作为一线诱导和维持治疗，让更多的MCL患者获得更佳的缓解和更长的无进展生存和总体生存。未来，第三代BTK抑制剂也会布局到更多适应症中。
参考来源：
1. Hematology Oncology Committee of China Anti-Cancer Association; Society of Hematology at Chinese Medical Association; Union for China Lymphoma Investigator at Chinese Society of Clinical Oncology. Zhonghua Xue Ye Xue Za Zhi. 2022;43(7):529-536. doi:10.3760/cma.j.issn.0253-2727.2022.07.001
2. 信达生物官网
3. 礼来官网
4. 行业深度报告 BTK 抑制剂问世开启靶向治疗，新型疗法突破耐药难题, 平安证券
5. Cool, Allison, et al. "BTK inhibitors: past, present, and future." Trends in Pharmacological Sciences (2024).
6. Stanchina, Michele D., et al. "Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemia." Nature Reviews Clinical Oncology (2024): 1-21.
关于贝壳社
贝壳社是国内领先的医健创新创业服务平台，为医健创业者提供全路径创业服务。通过产业空间运营、创业教育、投资孵化、数字化赋能、企业价值增长等服务体系，给医健创业企业提供产业空间、人才战略培养、投融资、产业生态资源、数字化转型等服务。同时，贝壳社布局澳洲，帮助国内生物医药企业加速走向海外；成立“泰格-泰珑-贝壳社企业经营服务中心”为企业成长提供全生命周期的增值服务，提高企业运营效率，加快企业成长发展。我们深度链接政府、科研院所、临床机构、投资机构、第三方服务商、CXO等行业资源，致力于赋能医疗健康创业公司成长，推动创新技术造福人类生命健康。
往
期
推
荐
1
百亿大药，难逃“内卷”魔咒
2
破局！国内首款CD19 ADC药物获批上市
_
3
最饥渴的大厂，全力扫货中国
_
*声明：本文仅为作者观点，不构成任何投资建议，且非治疗方案推荐。
投稿请添加小助手：bioclub666
临床2期上市批准引进/卖出临床申请
2024-12-10
2024年11月30日-12月1日，第九届医药创新与投资大会（以下简称“创投大会”）非上市公司路演专场（以下简称“非上市专场”）首次在广州举办。非上市专场共有29个路演项目脱颖而出，在创投大会两天的活动中，向投资者、合作伙伴及行业专家展示了不同治疗领域的前沿成果与巨大潜力。
非上市专场精心策划3场盛会，旨在为医药创新项目提供国际展示舞台，携手业界同行共谋发展。专场特邀三位行业翘楚担任主持：西南证券研发中心副所长、医药首席分析师杜向阳先生，华英证券（国联证券全资投行子公司）执行董事、原国联证券研究所负责人杨烨辉先生，以及北康医疗投资总经理何风志先生，为与会嘉宾带来了一场场思想碰撞与智慧交流的盛宴。
从左至右：西南证券研发中心副所长，医药首席分析师杜向阳先生；华英证券（国联证券全资投行子公司）执行董事，原国联证券研究所负责人杨烨辉先生；北康医疗投资总经理何风志先生
开场报告引领行业新视野
本届非上市专场，珠海横琴濠麦科技有限公司总经理兼董事长龚元香女士带来“大数据赋能立项研发与交易：从‘预见未来’到‘遇见未来’”的开场报告，深入探讨了医药行业在资产交易、产品立项及研发策略方面的关键议题，着重阐述了运用大数据分析及全面考量的策略，以促进产品国际化并吸引买家关注。
珠海横琴濠麦科技有限公司总经理兼董事长龚元香女士
建银国际金融有限公司联席董事总经理王晓坤先生深入剖析了“香港资本市场医疗行业热点问题”和“生物医药企业港股上市热点问题”。聚焦于香港资本市场及医疗行业的最新动态，包括近期资本市场关注点、香港医疗板块表现、香港上市优势、18A板块情况以及主板上市相关细节，为与会者提供了新的思路和宝贵的行业洞察。
建银国际金融有限公司联席董事总经理王晓坤先生
精彩路演项目介绍
武汉益承生物致力于开发治疗炎症和自身免疫性疾病的创新药，旗下的抗炎创新药物-伊匹乌肽是全球首个针对PI3K调节亚基（RS）成员p55PIK的特异性抑制剂，对人体不产生毒副作用，可应用于炎症和自身免疫性疾病的治疗，同时，作为全球专利保护药，凭借优于现有抗炎药、患者人数众多、可自由定价等因素，能创造良好经济效益。
维昇药业是专注于内分泌相关治疗领域的创新型生物医药公司，主要产品隆培促生长素是首个在美国及欧洲获批上市的用于治疗儿童生长激素缺乏症的长效生长激素，旨在通过每周一次用药，帮助生长激素缺乏的儿童达到或接近正常身高，经全球及中国3期临床试验证实，隆培促生长素是截至目前唯一优效于生长激素日制剂的长效生长激素。其在中国的上市许可申请（BLA）于2024年获得中国国家药品监督管理局（NMPA）正式受理，用于治疗儿童生长激素缺乏症。
神曦生物是由陈功教授在美国宾夕法尼亚州立大学做教授期间创立，拥有200多项发明专利申请，已获得国际范围内的57项专利授权，核心技术是原位神经再生基因疗法，将脑内丰富的可分裂的星形胶质细胞直接转化为功能性神经元，建立基于该成果进行大脑修复的平台技术，适用于许多重大脑疾病的治疗，包括脑中风，阿尔兹海默症，胶质瘤，帕金森病，亨廷顿舞蹈症，创伤性脑损伤，以及视网膜疾病，脊髓损伤和渐冻症等。今年3月，由神曦生物自主研发的AAV-NeuroD1基因治疗产品NXL-004成功完成首例患者给药。这是全球首例AAV-NeuroD1基因疗法临床用药，标志着这一全新的基因疗法正式进入临床研究阶段。
麓鹏制药核心项目洛布替尼是自主开发的一款小分子布鲁顿酪氨酸激酶抑制剂(BTKi)，拥有其包括中国在内的全球范围的知识产权，除针对有关自身免疫性疾病等非肿瘤适应症以外，洛布替尼正在开展的临床研究适应症主要为各类复发难治B细胞淋巴瘤，主要有复发难治（R/R）成人套细胞淋巴瘤（R/R MCL），慢性淋巴细胞白血病/小淋巴细胞淋巴瘤（R/R CLL/SLL）、边缘区淋巴瘤（R/R MZL）和弥漫性大B细胞淋巴瘤(R/R DLBCL) 。对于复发难治性的非生发中心弥漫大B细胞淋巴瘤（R/R non-GCB DLBCL），洛布替尼与其他疗法相比，显示了特别优异的疗效，并于2024年5月在中国被国家药品监督管理局药品审评中心（CDE）纳入突破性治疗品种名单，为中国首个被认定为DLBCL突破性疗法的BTKi。
滨会生物起初致力于溶瘤病毒药物研发，发展至今建立了核酸、蛋白及细胞治疗等技术平台，核心管线溶瘤病毒OH2是全球首个进入临床试验的Ⅱ型单纯疱疹病毒一类新药，获CDE突破性疗法认证、美国孤儿药资格认证与快速通道资格，已完成临床前及Ⅰ、Ⅱ期研究，进入Ⅲ期临床研究阶段。2018年以来随着项目推进，累计融资超过10亿元人民币。
越洋医药是一家以特色平台技术为核心、以满足临床未满足的需求为驱动力的国际化改良型新药研发公司，专注于在固体口服缓控释细分领域深耕细作，独立自主开发了一系列特色缓控释平台技术，比如Dual-trol、Dual-lease、Bi-lock、Mech-trol等，多个平台技术已在中国、美国、欧洲和日本获得发明专利授权，体现了其国际化的市场布局，并已应用于针对不同适应症、不同化合物的缓控释新药开发，构建了一定的技术壁垒和门槛。
在这场非上市专场的路演盛宴中，我们见证了医药创新的火花碰撞，感受到了投资者对未来的热切期待。非上市专场历经九届，始终紧紧伴随医药创新与投资浪潮的脉搏，与业内同行携手并肩，砥砺前行，期待下一次相聚，共话发展！
会议现场
------------------------------
「长按」二维码添加小达「进群」
与更多行业伙伴共探市场前沿资讯
艾美达医药咨询
艾美达（北京）医药信息咨询有限公司，成立于2014年4月，是一家专业的医药行业咨询服务提供商。公司致力于将产业政策研究与真实世界的数据挖掘深度结合，洞悉行业政策对市场的影响，通过专业的研究提供前瞻性的市场分析，为企业产品上市后的市场准入提供整体解决方案。
临床3期专利到期
2024-11-28
Advances in immunotherapy have ushered in a new era of treatment for follicular lymphoma (FL), particularly for patients who have experienced relapse after conventional chemotherapy regimens. This paradigm shift is characterized by the emergence of innovative therapies like CAR T-cell therapy and bispecific antibodies, which have demonstrated remarkable efficacy in targeting and eradicating lymphoma cells.
CAR T-cell therapy represents a groundbreaking approach where a patient's own T-cells are genetically engineered to recognize and attack cancer cells. This personalized treatment has shown significant promise, especially for individuals who have undergone extensive previous therapies. One notable example is Axicabtagene ciloleucel (Yescarta), a CAR T-cell therapy approved for use in patients with relapsed or refractory follicular lymphoma. Clinical trials have highlighted its ability to induce durable remissions, with some patients experiencing long-term remission even after multiple prior therapies.
LAS VEGAS, Nov. 28, 2024 /PRNewswire/ -- DelveInsight's
'
Follicular Lymphoma Pipeline Insight 2024
' report provides comprehensive global coverage of pipeline follicular lymphoma therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the follicular lymphoma pipeline domain.
Key Takeaways from the Follicular Lymphoma Pipeline Report
DelveInsight's follicular lymphoma pipeline report depicts a robust space with
50+ active players working to develop
55+ pipeline therapies for follicular lymphoma treatment.
Key follicular lymphoma companies such as
Chia Tai Tianqing Pharmaceutical Group, Incyte Corporation, Mabworks, Johnson & Johnson Innovative Medicine, Nektar Therapeutics, Xynomic Pharmaceuticals, Merck Sharp & Dohme, Jiangsu HengRui Medicine Co., Ltd., ADC Therapeutics, Bristol-Myers Squibb, Swedish Orphan Biovitrum, Zhejiang DTRM Biopharma, Immpact Bio, Galapagos, Immunitas Therapeutics, Enterome, CRISPR Therapeutics, CHO Pharma, Shanghai Blueray Biopharma, BeiGene, AstraZeneca, AVM Biotechnology, Mustang Bio, Merck, Pell Bio-Med Technology, Schrodinger Inc., Sana Biotechnology, Poseida Therapeutics, OncoNano Medicine, Inc., Nurix Therapeutics, Inc., NovalGen, Pfizer, Xencor, Wellington Zhaotai Therapies, MEI Pharma, Sutro Biopharma, Synthekine, Verismo Therapeutics, Vincerx Pharma, Novartis, Century Therapeutics, Newave Pharmaceuticals, Bio-Path Holdings, Affimed GmbH, Iksuda Therapeutics, Allogene Therapeutics, Adicet Bio, Carna Biosciences, Inc., BeiGene, Boryung Pharmaceutical, Accutar Biotechnology, Atara Biotherapeutics, AbbVie, InnoCare Pharma, NeoImmuneTech, and others are evaluating new follicular lymphoma drugs to improve the treatment landscape.
Promising follicular lymphoma pipeline therapies such as
Parsaclisib, TQ-B3525, Tafasitamab, MIL62, Ibrutinib, AZD0486, NKTR-255, Abexinostat, Acalabrutinib, Zilovertamab vedotin, SHR2554, Nivolumab, Loncastuximab tesirine, Golcadomide, Emapalumab, DTRM-555, Capivasertib, IMPT 314, GLPG5101, IMT-009, EO2463, CTX112, CHO-H01, BR1733, BGB-16673, BGB-10188, AZD5492, AVM0703, MB106, MK-1026, PL001, SGR-1505, SC291, SC262, P-CD19CD20-ALLO1, ONM 501, NX-5948, NX 2127, NVG-111, Mevrometostat, Plamotamab, WZTL-002, Voruciclib, STRO001, SYNCAR-001 + STK-009, SynKIR-310, VIP-152, VAY736, CNTY-101, LP-168, BP1002, IOA-244, IKS 03, ALLO-501, ADI-001, AS-1763, BGB-21447, BR101801, AC676, ATA3219, ABBV-319, ABBV-101, ICP-B02, ICP-B05, C-CAR039, Efineptakin Alfa, and others are under different phases of follicular lymphoma clinical trials.
In August 2024, the company expects to file a supplemental Biologics License Application for tafasitamab for the treatment of patients with FL who have failed at least one prior systemic anti-CD20 immunotherapy or chemo-immunotherapy by the end of 2024 based on the positive Phase III results.
In June 2024, a consortium of Eugene Private Equity and Korea Development Bank Private Equity announced that they would acquire 80% of South Korean vaccine maker Boryung Biopharma Co. for 320 billion won (USD 231 million).
In February 2024, Incyte announced that it had entered into an asset purchase agreement with MorphoSys AG, which gives Incyte exclusive global rights for tafasitamab. Incyte will now recognize revenue and cost for all US commercialization and clinical development and MorphoSys will no longer be eligible to receive future milestone, profit split and royalty payments.
In September 2023, OncoNano Medicine, Inc. announced a clinical trial supply agreement with Regeneron for the use of Libtayo (cemiplimab), a PD-1 inhibitor, in the combination stage of the first human trial of ONM-501, a dual-activating STING (STimulator of INterferon Genes) agonist and lead therapeutic development candidate. The ONM-501 first-in-human trial is a multicenter Phase Ia/b dose escalation and dose expansion study of intratumoral ONM-501 as monotherapy and in combination with Libtayo in patients with advanced solid tumors and lymphomas. OncoNano is the sponsor of the clinical trial, and Regeneron will supply cemiplimab.
In May 2023, Janssen Pharmaceutical Companies of Johnson & Johnson announced that it had entered into a worldwide collaboration and license agreement with Cellular Biomedicine Group Inc. (CBMG) to develop, manufacture, and commercialize next-generation chimeric antigen receptor (CAR) T-cell therapies for the treatment of B-cell malignancies. Under the terms of the agreement, CBMG will grant Janssen a worldwide license to develop and commercialize the CAR-T assets, except in Greater China. Janssen and CBMG will negotiate an option for Janssen to commercialize the products in the Chinese territory. Janssen will make an upfront payment of USD 245 million that will be accounted for in the second quarter as a research and development expense. Additional future payments will be based upon achieving certain development, regulatory, and sales milestones, as well as tiered royalty payments on worldwide net trade sales, excluding Greater China.
Request a sample and discover the recent advances in follicular lymphoma treatment drugs @
Follicular Lymphoma Pipeline Report
The follicular lymphoma pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage follicular lymphoma drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the follicular lymphoma clinical trial landscape.
Follicular Lymphoma Overview
Follicular lymphoma is a common type of non-Hodgkin lymphoma (NHL) that originates from B-cells, a kind of white blood cell responsible for producing antibodies. This cancer is characterized by the growth of abnormal lymphoid follicles, which can disrupt normal lymphatic function. While the exact causes of follicular lymphoma are not fully understood, certain factors may increase the risk, including age (most commonly affecting adults over 60), a family history of lymphoma, and potential environmental factors such as exposure to pesticides or chemicals.
Symptoms of follicular lymphoma can vary widely but may include painless swelling of lymph nodes in the neck, armpit, or groin, unexplained weight loss, night sweats, fatigue, and fever. Some patients may remain asymptomatic for extended periods, as this type of lymphoma can progress slowly. Diagnosis typically involves a combination of physical examinations, blood tests, imaging studies (like CT scans), and a biopsy of affected lymph nodes. The biopsy helps determine the subtype and stage of the lymphoma, which is crucial for planning treatment.
Treatment for follicular lymphoma depends on the stage of the disease and the patient's overall health. Options may include watchful waiting for asymptomatic cases, chemotherapy, immunotherapy (such as monoclonal antibodies), and targeted therapies. In some cases, stem cell transplants may be considered for patients with more aggressive forms or those who do not respond to initial treatments. Given the indolent nature of follicular lymphoma, ongoing management, and regular monitoring are vital for achieving the best possible outcomes.
Find out more about follicular lymphoma treatment drugs @
Drugs for Follicular Lymphoma Treatment
A snapshot of the Follicular Lymphoma Pipeline Drugs mentioned in the report:
Learn more about the emerging follicular lymphoma pipeline therapies @
Follicular Lymphoma Clinical Trials
Follicular Lymphoma Therapeutics Assessment
The follicular lymphoma pipeline report proffers an integral view of the follicular lymphoma emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.
Scope of the Follicular Lymphoma Pipeline Report
Coverage: Global
Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Therapeutics Assessment
By Route of Administration: Intra-articular, Intraocular, Intrathecal, Intravenous, Oral, Parenteral, Subcutaneous, Topical, Transdermal
Therapeutics Assessment
By Molecule Type: Oligonucleotide, Peptide, Small molecule
Therapeutics Assessment
By Mechanism of Action: Phosphatidylinositol 3 kinase delta inhibitors, Phosphatidylinositol 3 kinase gamma inhibitors, Emt protein-tyrosine kinase inhibitors, Interleukin 15 receptor agonists, Histone deacetylase inhibitors, Rad51 recombinase inhibitors, Agammaglobulinaemia tyrosine kinase inhibitors, Apoptosis stimulants, Cell cycle inhibitors, Tubulin inhibitors, Tubulin polymerisation inhibitors, Enhancer of zeste homolog 2 protein inhibitors, Antibody-dependent cell cytotoxicity, Programmed cell death 1 receptor antagonists, T lymphocyte stimulants, Alkylating agents, DNA cross-linking agents
Key Follicular Lymphoma Companies: Chia Tai Tianqing Pharmaceutical Group, Incyte Corporation, Mabworks, Johnson & Johnson Innovative Medicine, Nektar Therapeutics, Xynomic Pharmaceuticals, Merck Sharp & Dohme, Jiangsu HengRui Medicine Co., Ltd., ADC Therapeutics, Bristol-Myers Squibb, Swedish Orphan Biovitrum, Zhejiang DTRM Biopharma, Immpact Bio, Galapagos, Immunitas Therapeutics, Enterome, CRISPR Therapeutics, CHO Pharma, Shanghai Blueray Biopharma, BeiGene, AstraZeneca, AVM Biotechnology, Mustang Bio, Merck, Pell Bio-Med Technology, Schrodinger Inc., Sana Biotechnology, Poseida Therapeutics, OncoNano Medicine, Inc., Nurix Therapeutics, Inc., NovalGen, Pfizer, Xencor, Wellington Zhaotai Therapies, MEI Pharma, Sutro Biopharma, Synthekine, Verismo Therapeutics, Vincerx Pharma, Novartis, Century Therapeutics, Newave Pharmaceuticals, Bio-Path Holdings, Affimed GmbH, Iksuda Therapeutics, Allogene Therapeutics, Adicet Bio, Carna Biosciences, Inc., BeiGene, Boryung Pharmaceutical, Accutar Biotechnology, Atara Biotherapeutics, AbbVie, InnoCare Pharma, NeoImmuneTech, and others.
Key Follicular Lymphoma Pipeline Therapies: Parsaclisib, TQ-B3525, Tafasitamab, MIL62, Ibrutinib, AZD0486, NKTR-255, Abexinostat, Acalabrutinib, Zilovertamab vedotin, SHR2554, Nivolumab, Loncastuximab tesirine, Golcadomide, Emapalumab, DTRM-555, Capivasertib, IMPT 314, GLPG5101, IMT-009, EO2463, CTX112, CHO-H01, BR1733, BGB-16673, BGB-10188, AZD5492, AVM0703, MB106, MK-1026, PL001, SGR-1505, SC291, SC262, P-CD19CD20-ALLO1, ONM 501, NX-5948, NX 2127, NVG-111, Mevrometostat, Plamotamab, WZTL-002, Voruciclib, STRO001, SYNCAR-001 + STK-009, SynKIR-310, VIP-152, VAY736, CNTY-101, LP-168, BP1002, IOA-244, IKS 03, ALLO-501, ADI-001, AS-1763, BGB-21447, BR101801, AC676, ATA3219, ABBV-319, ABBV-101, ICP-B02, ICP-B05, C-CAR039, Efineptakin Alfa, and others.
Dive deep into rich insights for new drugs for follicular lymphoma treatment, visit @
Follicular Lymphoma Drugs
Table of Contents
For further information on the follicular lymphoma pipeline therapeutics, reach out @
Follicular Lymphoma Treatment Drugs
Related Reports
Follicular Lymphoma Market
Follicular Lymphoma Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key follicular lymphoma companies including
Epizyme, Eisai, Bayer Healthcare Pharmaceuticals, Verastem Oncology, Gilead Sciences, TG Therapeutics, Bristol-Myers-Squibb, Roche, Incyte Corporation, Bristol Myers Squibb, ADC Therapeutics, MorphoSys, Nordic Nanovector, AbbVie, Regeneron Pharmaceuticals, Janssen Research & Development, Novartis, MEI Pharma, and BeiGene, among others.
Non-Hodgkin Lymphoma Market
Non-Hodgkin Lymphoma Market Insights, Epidemiology, and Market Forecast
– 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key Non-Hodgkin lymphoma companies, including
Roche, Pfizer, Amgen, Novartis, Teva Pharmaceuticals, Genentech, ACD Therapeutics, among others.
Non-Hodgkin Lymphoma Pipeline
Non-Hodgkin Lymphoma Pipeline Insight
– 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Non-Hodgkin lymphoma companies, including
Novartis, AstraZeneca, Genentech, BioInvent, Genmab, SystImmune, Nordic Nanovector, Pacylex Pharmaceuticals, Artiva Biotherapeutics, Inc., Chipscreen Biosciences, Ltd., Timmune Biotech Inc., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Gilead Sciences, Acerta Pharma BV, Adagene Inc, Conjupro Biotherapeutics, Inc., Rhizen Pharmaceuticals, Juventas Cell Therapy Ltd., Incyte Corporation, HUYA Bioscience International, SecuraBio, Genor Biopharma Co., Ltd., Kyowa Kirin Co., Ltd., Antengene Therapeutics Limited, Regeneron Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., Xynomic Pharmaceuticals, Inc., BioTheryX, Inc., UWELL Biopharma, Kronos Bio, Bio-Thera Solutions, Spectrum Pharmaceuticals, Inc., Aptose Biosciences Inc., Miltenyi Biomedicine GmbH, Precision BioSciences, Inc., Teneobio, Inc., TCR2 Therapeutics, IGM Biosciences, Inc, among others.
Diffuse Large B-cell Lymphoma Market
Diffuse Large B-cell Lymphoma Market Insights, Epidemiology, and Market Forecast
– 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key DLBCL companies, including
AbbVie, Genmab, Merck, Roche, Xencor, Janssen, Denovo Biopharma, Calithera Biosciences IMV, Biogen, Autolus Therapeutics, Allogene Therapeutics, Novartis, Miltenyi Biomedicine, Regeneron Pharmaceuticals, Debiopharm, Seagen, Takeda, AstraZeneca, Gilead Sciences, among others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve
.
Contact Us
Shruti Thakur
[email protected]
+14699457679
Logo:
SOURCE DelveInsight Business Research, LLP
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
440k+
Newsrooms &
Influencers
9k+
Digital Media
Outlets
270k+
Journalists
Opted In
GET STARTED
免疫疗法引进/卖出临床3期疫苗细胞疗法
100 项与 洛布替尼 相关的药物交易
登录后查看更多信息
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 难治性套细胞淋巴瘤 | 临床2期 | 中国 | 2023-02-21 | |
| B细胞恶性肿瘤 | 临床1期 | 中国 | 2023-12-20 | |
| 多发性硬化症 | 临床1期 | 中国 | 2022-05-10 | |
| 视神经脊髓炎 | 临床1期 | 中国 | 2022-05-10 | |
| 慢性淋巴细胞白血病 | 临床1期 | 美国 | 2021-07-19 | |
| 弥漫性大B细胞淋巴瘤 | 临床1期 | 美国 | 2021-07-19 | |
| 滤泡性淋巴瘤 | 临床1期 | 美国 | 2021-07-19 | |
| 毛细胞白血病 | 临床1期 | 美国 | 2021-07-19 | |
| 套细胞淋巴瘤 | 临床1期 | 美国 | 2021-07-19 | |
| 边缘区B细胞淋巴瘤 | 临床1期 | 美国 | 2021-07-19 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
| 研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
|---|
N/A | - | - | 獵襯糧積襯願憲積壓製(構鹹網築膚範蓋淵鹹積) = TEAE seen in >20% of pts included nausea, constipation, headache, abdominal pain, cough, diarrhea, dizziness, fatigue, petechiae; of those, grade 3 or higher AE included constipation and fatigue in 1 pt each. Serious AEs (scrotal infection, pneumonia, middle ear inflammation, altered state of consciousness) were seen in 4 pts, with dose interruption in one. No atrial fibrillation/flutter has been reported. No Grade 3 or higher hypertension has been reported in this GM cohort. Grade 3 or higher infection (scrotal infection and pneumonia) and neutropenia are seen in 3 pts (scrotal infection, neutropenia, neutropenia and pneumonia). 1 pt experienced low-grade bleeding and 4 pts experienced low-grade bruising. 鑰願顧餘鏇築簾範鑰餘 (壓糧齋構壓憲憲憲憲願 ) | - | 2024-12-09 | ||
N/A | - | 鏇壓積積簾艱鑰鏇窪鬱(顧夢築觸鏇鑰鑰糧網蓋) = lung infection, not related to rocbrutinib 鬱顧憲淵齋積廠壓觸鏇 (鹽夢襯構繭網齋窪蓋鑰 ) 更多 | - | 2024-12-08 | |||
N/A | - | 窪淵醖蓋壓鬱鏇選網鏇(鑰選夢積壓壓願醖築範) = 選製廠憲夢鹽願窪鹹鏇 繭壓襯膚鏇夢鹹醖衊廠 (遞壓鑰製構鑰艱積鹹選 ) | - | 2024-12-08 | |||
窪淵醖蓋壓鬱鏇選網鏇(鑰選夢積壓壓願醖築範) = 獵觸構鏇範觸鹽鹽蓋鏇 繭壓襯膚鏇夢鹹醖衊廠 (遞壓鑰製構鑰艱積鹹選 ) | |||||||
临床1期 | 30 | Rocbrutinib 100mg | 願憲襯構觸壓廠憲襯艱(積簾鹹衊遞蓋構齋範蓋) = 襯鹽壓顧齋糧艱襯繭鹽 獵壓鏇鹹網範壓範鬱簾 (醖顧淵選遞衊獵醖齋簾 ) 更多 | 积极 | 2024-12-07 | ||
Rocbrutinib 150mg | 製網艱醖製觸築齋夢積(憲願醖窪窪廠範憲構顧) = 選衊淵膚範醖鑰糧鑰製 膚蓋網襯積簾膚願顧醖 (壓襯鏇鑰夢艱膚積網範 ) | ||||||
临床1期 | 68 | 築蓋構製鏇遞鹽憲艱壓(膚餘壓範廠鑰顧夢觸鑰) = 鬱鹽鏇廠觸鏇醖窪願糧 齋窪壓鏇遞蓋構糧壓夢 (鹹顧網蓋鹹願構襯醖積 ) | - | 2023-12-11 | |||
临床1期 | - | 鏇顧襯衊鬱選範醖築構(窪鏇餘網憲齋範鹹鏇糧) = 艱製簾淵蓋齋艱淵遞積 廠壓遞簾醖壓觸鏇艱齋 (觸遞範鏇壓蓋膚獵鏇醖 ) 更多 | - | 2023-12-10 | |||
临床1期 | 43 | 淵憲願膚顧觸淵襯鏇蓋(顧簾顧襯襯顧蓋鬱願壓) = 鑰窪構艱選廠糧壓觸選 衊壓鑰鑰鏇遞艱廠顧鬱 (憲網鑰網製憲願齋廠鏇 ) | - | 2023-12-09 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
标准版
¥16800
元/账号/年
新药情报库 ｜ 省钱又好用！
立即使用
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用